Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay
Status:
Completed
Trial end date:
2014-11-17
Target enrollment:
Participant gender:
Summary
This clinical trial uses a laboratory test called a high throughput sensitivity assay in
planning treatment for patients with relapsed or refractory acute myeloid leukemia. The aim
is to try to identify drugs that may be effective in killing leukemia cells for those
patients who will not be cured with conventional chemotherapy. This assay will test multiple
drugs simultaneously against a patient's own donated blood sample. The goal is to use this
laboratory assay to best match a drug to a patient's disease.